disease 1,609 words KG: ent-dise-01761651
Contents

LATE (Limbic-Predominant Age-Related TDP-43 Encephalopathy)

Disease Info
TDP-43 PathologyPhosphorylated, ubiquitinated, and truncated TDP-43 inclusions
Limbic PredominancePrimary involvement of amygdala, hippocampus, and entorhinal cortex
Age AssociationTypically onset after age 80
Clinical PhenotypeAmnestic syndrome resembling AD but with distinct progression
Age 70-79Approximately 5-10% prevalence
Age 80-89Approximately 15-20% prevalence
Age 90+Up to 25-30% prevalence in some cohorts
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Related Hypotheses (11)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
APOE Isoform Conversion Therapy
Score: 0.72
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.63

Related Analyses (7)

What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived

Related Experiments (8)

Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an
validation · proposed · Score: 0.40

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)